This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lefrere F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16: 587–593.
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571.
Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775–779.
Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274–1276.
Raje N, Anderson K . Thalidomide a revival story. N Engl J Med 1999; 341: 1606–1609.
D'Amato RJ, Loughnan MS, Flynn E, Folkman J . Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994; 91: 4082–4085.
Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999; 163: 380–386.
Haslett PAJ, Corral LG, Albert M, Kaplan G . Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 1885–1892.
Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210–216.
Mohty M, Stoppa AM, Blaise D, Isnardon D, Gastaut JA, Olive D et al. Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. J Leukocute Biol 2002; 72: 939–945.
Keifer JA, Guttridge DC, Ashburner BP, Baldwin Jr. AS . Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity. J Biol Chem 2001; 276: 22382–22387.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Damaj, G., Lefrère, F., Delarue, R. et al. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 17, 1914–1915 (2003). https://doi.org/10.1038/sj.leu.2403058
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403058
This article is cited by
-
Cereblon: promise and challenges for combating human diseases
Pflügers Archiv - European Journal of Physiology (2021)
-
B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy
Angiogenesis (2020)
-
Cereblon in health and disease
Pflügers Archiv - European Journal of Physiology (2016)
-
Therapeutic effects of thalidomide in hematologic disorders: a review
Frontiers of Medicine (2013)
-
Management of Mantle Cell Lymphoma in the Elderly: Current and Potential Strategies
Drugs & Aging (2013)